INTRODUCTION
============

The incidence of cancer has been estimated to increase dramatically in the elderly population, from 1.6 million in 2010 to 2.3 million in 2030 in the United States \[[@B1]\]. Due to the lengthening of life expectancy, 70% of all cancer diagnoses will occur in elderly patients and, despite the substantial improvements made in treatment and prevention strategies, the number of deaths from cancer has expected to rise further \[[@B1][@B2][@B3]\].

Older age is a poor prognostic factor in ovarian cancer (OC), and the management of a disease that predominantly affects an "elderly" population is a challenge. At present, the standard of care of OC was defined by the results of 2 randomized trials (ICON-7 and GOG218) that established the activity of bevacizumab in combination with 3-weekly paclitaxel and carboplatin for the first line treatment \[[@B4][@B5]\]. The safety of bevacizumab was investigated in subgroup analyses from 3 international studies (AURELIA, OTILIA and ROSiA), but data on elderly population were scant, mainly because these patients are under-represented in clinical trials \[[@B6][@B7][@B8]\]. The studies concluded that older age should not preclude the use of antiangiogenetic drugs, although a geriatric assessment is required in order to improve the appropriate selection of patients.

The application of a geriatric assessment in oncology is becoming crucial because it is valued as an indicator of risk stratification in older cancer patients. In this scenario, clinical criteria to adequately select elderly patients who can benefit from the efficacy of bevacizumab under safe conditions are needed. The aims of this single institution retrospective study were 1) to assess the tolerability of bevacizumab; 2) to identify predictors of developing toxicity from bevacizumab administration in elderly patients affected by OC.

MATERIALS AND METHODS
=====================

To address the study purposes, we identified from our electronic database a consecutive series of patients affected by primary advanced or recurrent OC, who received a bevacizumab-based treatment, admitted at the Gynaecologic Oncology Unit, Fondazione Policlinico A. Gemelli IRCCS in Rome, between January 2015 and December 2016. This case-control study was approved by the Institutional Review Board (n° prot. approval. IST CICOG-31-10-18\\123).

All patients included in the analysis should have received primary debulking surgery; no case of bevacizumab given in the neoadjuvant setting has been included. As first-line chemotherapy we administered carboplatin (area under the curve \[AUC\] 5) plus paclitaxel (175 mg/mq) and bevacizumab (15 mg/kg) for 6 cycles followed by 16 cycles of maintenance therapy with bevacizumab (15 mg/kg) q21, while for platinum-sensitive OC relapse we administered carboplatin (AUC 4) plus gemcitabine 800 mg/mq or paclitaxel 175 mg/mq and bevacizumab (15 mg/kg) followed by bevacizumab maintenance therapy until disease progression. Patients receiving other bevacizumab combinations in the recurrent setting were excluded.

Clinical charts were retrospectively reviewed and patient characteristics at initial diagnosis (demographics, comorbidities, Eastern Cooperative Oncology Group \[ECOG\] performance status \[PS\], tumor stage, histological type, tumor grade), surgical procedures, perioperative complications, chemotherapy treatment, and follow-up status were reported for each patient. Items for chemotherapy included the administered drugs, number of cycles, hematological and nonhematological toxicities, dose intensity, dose reductions, treatment delays, treatment discontinuation, PS according to ECOG at the end of chemotherapy, and number of chemotherapy lines administered.

In order to identify potential predictors of toxicity from bevacizumab, we considered factors generally recognized to hinder bevacizumab use, such as advanced age (≥65 years) \[[@B9]\], and kidney failure (creatinine serum levels \>1.1 mg/dL) \[[@B10]\]. Other factors of interest in the field of geriatric oncologic assessment associated to worse outcomes were included such as a high comorbidity burden (≥3 comorbidities), polypharmacy, defined as the concomitant use of ≥5 drugs \[[@B11]\] and ECOG ≥1 \[[@B12]\]. The estimated glomerular filtration rate (eGFR) according to Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) \[[@B13]\], recently suggested to accurately predict renal impairment in the elderly with cancer \[[@B14]\], was also included.

Patients were divided into 2 groups according to age category: \<65 years (group 1) and ≥65 years (group 2) \[[@B9]\] and surgical and medical treatments with the related complications and toxicities were analyzed according to patient age cut-off value. Chi-square or Fisher\'s exact test were used for comparison of categorical variables. A binary logistic model was applied to determine the effect of independent variables as previously defined on the risk of toxicity. Regarding survival analysis, progression free survival (PFS) was defined as the time elapsed between the date of diagnosis (staging laparoscopy) and recurrence. Medians and life tables were computed using the product limit estimate by the Kaplan-Meier method, and the log-rank test was used to assess statistical significance.

In addition to standard statistics, a decision tree methodology was applied to define significant clinical predictors of severe toxicity rate. The following predictor variables were used: ECOG, age, high grade serous OC, grade, comorbidities, BMI and creatinine. The dependent variable referred to severe toxicity (no or yes). An algorithmic rule --- that splits group into 2 groups that are internally as similar as possible --- was used to decide which variable to split and which splitting value to take at each step of the tree\'s construction \[[@B15]\]. To create the decision-tree the part package was used and the minimum error rule (size producing the minimum cross-validation error) was applied to determine the optimal tree size.

All statistical calculations were carried out using SPSS 20.0 for Mac (SPSS Inc., Chicago, IL, USA) and RStudio-0.98.1091 software.

RESULTS
=======

The study population included 283 women, receiving a bevacizumab containing treatment for primary advanced or recurrent epithelial OC. Mean age of the overall population was 55 years (±11.1, standard deviation), with 211 patients (74.6%) younger than 65 years (group 1) and 72 older patients (group 2). The majority of patients presented with FIGO stage IIIC at diagnosis (183; 68%) and with a serous histotype (248; 92.5%). Stage and histotype distribution were homogeneous among older and younger patients ([Table 1](#T1){ref-type="table"}).

###### Clinical characteristic of the overall population and according to age

![](jgo-31-e6-i001)

  Variable                               All cases                  Group 1 (age \<65 yr)   Group 2 (age ≥65 yr)   p-value     
  -------------------------------------- -------------------------- ----------------------- ---------------------- ----------- -------
  Patients                               283                        211 (74.6)              72 (25.4)              \-          
  Mean age (yr)                          55.6±11.1                  51±8.6                  70±3.0                 0.001       
  ECOG PS                                                                                                          0.001       
                                         0                          259 (91.5)              203 (96.2)             56 (77.8)   
                                         1                          24 (8.5)                8 (3.8)                16 (22.2)   
  Comorbidities^\*^                                                                                                0.001       
                                         0                          122 (43.1)              111 (52.6)             11 (15.3)   
                                         1                          88 (31.1)               69 (32.7)              19 (26.4)   
                                         2                          45 (15.9)               21 (10.0)              24 (33.3)   
                                         3+                         28 (9.9)                10 (4.7)               18 (25.0)   
  Comorbidities type                                                                                                           
                                         Hypertension               83 (29.3)               44 (20.9)              39 (54.2)   0.001
                                         Diabetes                   10 (3.5)                4 (1.9)                6 (8.3)     0.020
                                         Obesity                    5 (1.8)                 4 (1.9)                1 (1.4)     0.623
                                         CV disease                 38 (13.4)               20 (9.5)               18 (25.0)   0.001
                                         GI disease                 18 (6.4)                10 (4.7)               8 (11.1)    0.056
                                         Pulmonary                  9 (3.2)                 2 (0.9)                7 (9.7)     0.001
                                         Neurological               25 (8.8)                12 (5.7)               13 (18.1)   0.001
                                         Other cancer               0                       0                      0           \-
  Mean CR serum levels                   0.75±0.16                  0.73±0.15               0.82±0.18              0.010       
  Mean eGFR CDK-EPI                      88.68±18.01                93.15±16.83             75.58±14.70            0.001       
  Mean of assumed drugs                  1.10±1.65                  0.70±1.18               2.28±2.18              0.001       
  Histotype^†^                                                                                                     0.591       
                                         HGS                        248 (92.5)              186 (91.6)             62 (95.4)   
                                         Endometrioid               12 (4.5)                10 (4.9)               2 (3.1)     
                                         Other                      8 (3.0)                 7 (3.5)                1 (1.5)     
  Tumor grade                                                                                                      0.243       
                                         G1                         7 (2.6)                 7 (3.4)                0           
                                         G2                         7 (2.6)                 6 (3)                  1 (1.5)     
                                         G3                         254 (94.8)              190 (93.6)             64 (98.5)   
  FIGO stage^‡^                                                                                                    0.267       
                                         I--II                      11 (3)                  9 (4.4)                2 (3)       
                                         III--IV                    264 (93)                198 (95.6)             66 (97)     
  Surgical approach at primary surgery                                                                             0.001       
                                         PDS                        191 (68)                156 (74)               35 (51)     
                                         NACT+IDS                   92 (32)                 55 (26)                37 (49)     
  Perioperative complications^§^                                                                                               
                                         Abscess                    1 (0.3)                 0                      1 (1.5)     0.082
                                         Dehiscence                 2 (0.7)                 1 (0.4)                1 (1.5)     0.426
                                         Sub-occlusion              3 (1)                   3 (1.4)                0           0.305
                                         Sepsis                     2 (0.7)                 1 (0.4)                1 (1.5)     0.426
                                         Bleeding                   1 (0.3)                 0                      1 (1.5)     0.082
  Temporary/permanent stoma                                                                                        0.067       
                                         No                         242 (85)                185 (88)               57 (79)     
                                         Yes                        41 (15)                 26 (12)                15 (21)     
  Chemotherapy regimen                                                                                             0.035       
                                         CBDCA-PTX-BEV (1st line)   234 (82.7)              168 (79.6)             66 (91.7)   
                                         CBDCA-PTX-BEV (2nd line)   12 (4.2)                12 (5.7)               0 (0.0)     
                                         CBDCA-GEM-BEV (2nd line)   37 (13.1)               31 (14.7)              6 (8.3)     

Values are presented as number (%) or mean±standard deviation.

BEV, bevacizumab; CBDCA, carboplatin; CR, caloric restriction; CV, cardiovascular; ECOG PS, Eastern Cooperative Oncology Group performance status; eGFR CDK-EPI, estimated glomerular filtration rate according to Chronic Kidney Disease Epidemiology Collaboration equation \[[@B13]\]; FIGO, International Federation of Gynecology and Obstetrics; GEM, gemcitabine; GI, gastrointestinal; HGS, high-grade serous; NACT+IDS, neoadjuvant chemotherapy followed by interval debulking surgery; PDS, primary debulking surgery; PTX, paclitaxel.

^\*^Patients might have experiences more than 1 comorbidity; ^†^Data of 15 patients were missing; ^‡^Data of 8 patients were missing; ^§^Within 30 days after surgery.

The majority of patients (234, 82.7%) received carboplatin plus paclitaxel plus bevacizumab for 6 cycles, followed by maintenance therapy as first-line chemotherapy; treatment schedules are reported in [Table 1](#T1){ref-type="table"}. Among 49 patients who received bevacizumab at recurrence, 12 (5.4%) had antiangiogenic treatment both at first and second line; they were all younger than 65 years of age. Among those receiving bevacizumab in the first-line setting, median duration of therapy was 16 cycles (range 1--22), without differences age-related (17 cycles in the younger group compared with 15 cycles in the older, p=0.09) ([Fig. 1](#F1){ref-type="fig"}). Similarly, no difference was found in the recurrent setting, with a median of 20 cycles received in group 1, compared with 22 in group 2 (p=0.57).

![Summary of treatment exposure to bevacizumab maintenance in the first-line setting, in the all population and according to age.](jgo-31-e6-g001){#F1}

Overall, 161 of 283 (56.9%) patients had at least one comorbidity (range 1--6), and 126 (51.2%) did not assume any drug. Older patients presented with at least 1 comorbidity (61; 84.7%) and 18 (25%) had 3 or more comorbidities, compared with 10 (4.7%) in the younger population. Hypertension was the most reported comorbidity followed by cardiovascular disease among the older patients (54.2% and 25% of patients, respectively) ([Table 1](#T1){ref-type="table"}).

Accordingly, the number of assumed drugs was higher among the elderly patients, with 58 (80.6%) of them taking at least 1 medication and 28 (38.9%) taking 3 or more drugs, compared with 79 (37.4%) of the younger patients who received at least 1 medication (p\<0.001).

Creatinine serum levels and eGFR values were significantly higher and lower in the elderly group than in the younger population (p\<0.01 and p\<0.001, respectively, [Table 1](#T1){ref-type="table"}). Although most of the patients had ECOG PS equal to zero, a significantly higher number of the elderly had grade 1 compared to younger patients (16; 22.2% vs. 8; 3.8%; p\<0.001) ([Table 1](#T1){ref-type="table"}).

Twenty-seven (9.5%) patients reported grade 3 or 4 (G3/G4) toxicity in the whole population ([Table 2](#T2){ref-type="table"}), with 8 patients having more than one adverse event of grade 3 or worse. The most frequent adverse event reported was proteinuria (8, 2.8%), followed by gastrointestinal toxicity (7, 2.4%), venous thromboembolic event (6, 2.1%) and hypertension (6, 2.1%). No significant difference regarding type and number of toxicities were found between different age groups. Among the overall population and the age groups, 10 (4.7%, group 1) and 7 (9.7%, group 2) of women discontinued due to treatment related adverse events (p=0.355) ([Table 2](#T2){ref-type="table"}). None of patients in both groups discontinued due to worsening of pre-existing comorbidities.

###### Adverse events G3/G4 among patients and according to age
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  Variable                              All cases                                                      Group 1 (age \<65 yr)   Group 2 (age ≥65 yr)   p-value     
  ------------------------------------- -------------------------------------------------------------- ----------------------- ---------------------- ----------- -------
  Patients                              283                                                            211 (74.6)              72 (25.4)              \-          
  Patients with G3/G4 AEs               27 (9.5)                                                       19 (9.0)                8 (11.1)               0.599       
  BEV related G3/G4 AEs^\*^                                                                                                                                       
                                        Hematologic                                                    5 (1.97)                4 (1.9)                1 (1.4)     0.631
                                        Gastrointestinal (bowel perforation, subocclusion, volvulus)   7 (2.4)                 6 (2.8)                1 (1.4)     0.684
                                        Venous thromboembolic events                                   6 (2.1)                 4 (1.9)                2 (2.8)     0.643
                                        Arterial thromboembolic events/stroke/ictus                    1 (0.3)                 1 (0.5)                0           0.748
                                        Hypertension                                                   6 (2.1)                 5 (2.3)                1 (1.4)     0.535
                                        Proteinuria                                                    8 (2.8)                 4 (1.9)                4 (5.6)     0.112
                                        Chronic kidney failure^†^                                      8 (2.8)                 3 (1.4)                5 (7)       0.627
                                        Bleeding                                                       1 (0.3)                 1 (0.4)                0           0.554
                                        Wound healing complication                                     3 (1)                   2 (0.9)                1 (1.4)     0.753
                                        Fistula/abscess                                                1 (0.3)                 0                      1 (1.4)     0.082
                                        Congestive heart failure                                       0                       0                      0           NA
                                        Posterior reversible encephalopathy syndrome                   0                       0                      0           NA
                                        Arthralgia                                                     1 (0.3)                 0                      1 (1.4)     0.082
                                        Liver (high liver enzymes)                                     1 (0.3)                 1 (0.4)                0           0.554
  Main reason for BEV discontinuation                                                                                                                             
                                        Disease progression                                            96 (34)                 70 (33.1)              26 (36.1)   0.488
                                        Treatment related AEs                                          17 (6)                  10 (4.7)               7 (9.7)     0.355
                                        Worsening comorbidity                                          0                       0                      0           NA
                                        Other                                                          1 (0.3)                 1 (0.5)                0           0.956

Values are presented as number (%).

BEV, bevacizumab; AE, adverse event; eGFR CDK-EPI, estimated glomerular filtration rate according to Chronic Kidney Disease Epidemiology Collaboration equation.

^\*^Patient might have more than 1 AE; ^†^Expressed as eGFR CDK-EPI \<60 mL/min.

Among patients receiving carboplatin plus paclitaxel plus bevacizumab, 12 of them had previously received bevacizumab; these patients were younger than 65 years of age and none of them developed G3/G4 toxicity.

A logistic regression taking into account variables showing a statistically significant difference between young and elderly patients, was performed, to evaluate their association with the development of G3/G4 toxicity ([Table 3](#T3){ref-type="table"}). Interestingly, creatinine serum levels higher than 1.1 mg/dL (odds ratio \[OR\]=12.68; 95% confidence interval \[CI\]=2.92--55.07), eGFR \<60 mL/min (CKD-EPI) (OR=10.35; 95% CI=3.66--29.31), presence of 3 or more comorbidities (OR=6.60; 95% CI=1.87--23.36) were independently associated with a higher risk of developing G3/G4 toxicity. Conversely, neither being older than 65 years of age nor being on polypharmacy regimen were associated to toxicity.

###### Logistic regression of factors predictive of G3/G4 adverse events
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  Variable                             OR      95% CI        p-value
  ------------------------------------ ------- ------------- ---------
  Age ≥65 yr                           0.52    0.16--1.68    0.278
  ECOG PS ≥1                           2.18    0.50--9.47    0.298
  Comorbidies number ≥3                6.60    1.87--23.36   0.003
  Creatinine serum levels ≥1.1 mg/dL   12.68   2.92--55.07   0.001
  eGFR CDK-EPI \<60 mL/min             10.35   3.66--29.31   0.001
  Polypharmacy                         1.57    0.25--8.76    0.799

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; eGFR CDK-EPI: estimated glomerular filtration rate according to Chronic Kidney Disease Epidemiology Collaboration equation; OR, odds ratio.

Among those patients receiving bevacizumab maintenance in the first-line setting, median PFS was 17 vs. 11 months in patients younger than 65 years vs. older, respectively (p=0.09; [Fig. 2](#F2){ref-type="fig"}). Similarly, median PFS among those receiving bevacizumab in the recurrent setting was similar among groups (12 vs. 14 months, in patients younger than 65 years vs. older, respectively, p=0.87).

![PFS in patients receiving bevacizumab maintenance in the first-line setting: median PFS in group 1 (\<65 years) 17 months vs. 11 months in group 2 (≥65 years) (p=0.09).\
PFS, progression free survival.](jgo-31-e6-g002){#F2}

At this point, in order to produce a more useful classification, a decision tree algorithm has been proposed for the entire population. Creatinine level and comorbidities were of relative importance to predict severe toxicity in OC patients who received platinum-based chemotherapy plus bevacizumab. The split at the top of the tree resulted in 2 large branches: the left-hand branch included patients with creatinine level \<0.99 (93% of the overall sample, with 6% probability of severe toxicity); the right-hand branch corresponded to creatinine level ≥0.99 (7% of the overall sample, with 59% probability of severe toxicity). The right branch is further subdivided, in one step, by comorbidities (\<4 vs. ≥4). Details are shown in [Fig. 3](#F3){ref-type="fig"}.

![Classification tree for ovarian cancer patients who received platinum-based chemotherapy plus bevacizumab.](jgo-31-e6-g003){#F3}

DISCUSSION
==========

In the present study, we found that bevacizumab is not associated with an increase in G3/G4 toxicity among the elderly, suggesting that age per se is not a predictive factor of adverse events for those receiving bevacizumab.

Data about the use of bevacizumab in the specific setting of old patients, are available from the ROSiA study \[[@B7]\], which evaluated an extended duration of bevacizumab (up to 24 months) as frontline therapy for OC, and the single-arm OTILIA trial \[[@B8]\] assessing the safety and efficacy of carboplatin-paclitaxel plus bevacizumab in routine oncology practice. Although both agreed bevacizumab can be safely considered in the frontline treatment irrespective of age, our real-life study shows that its use is rarely considered in patients older than 65 years old.

In order to avoid exclusion of older patients from bevacizumab therapy, we then investigated some specific and simple clinical elements that can be considered when choosing chemotherapy schedule for OC patients. Indeed, in our study population, even if the number of comorbidities, number of assumed drugs, ECOG PS or serum creatinine level were reasonably higher among patients older than 65 years, G3/G4 toxicity were similar between the groups and the main reason for bevacizumab interruption was disease progression.

Results suggest that presence of renal dysfunction (as defined by creatinine serum levels ≥1.1 mg/dL or eGFR \<60 mL/min according to CKD-EPI equation) and a higher comorbidity burden (≥3) are significantly associated with G3/G4 toxicity in women receiving bevacizumab in maintenance ([Table 3](#T3){ref-type="table"}). In particular, the CKD-EPI equation, which was shown to give a more accurate GFR estimation of renal function, without additional laboratory costs, compared with other GFR measures \[[@B13]\] is one of the strongest predictive factors of developing G3/G4 toxicity. Interestingly, none of the 12 patients receiving 2 chemotherapy lines with bevacizumab complained of G3/G4 toxicity at second line treatment, confirming that it is a reasonable choice even as a rechallenge \[[@B16]\].

Given the retrospective observational nature of our study, several limitations should be noted. Nonetheless, we have also tried to overcome this issue by a decision tree analysis which further confirmed the limited value of age in the decision-process of elderly patients suitable for bevacizumab. Of course, results should be confirmed in a controlled prospective trial and further machine learning algorithms should be developed in order to identify predictive features of side effects in this setting of patients.

Furthermore, because patients with poorer ECOG PS might, in general, be less likely to receive bevacizumab in first-line treatment and more likely to experience adverse events, and as we were unable to control for factors that might have influenced treatment decision-making, our findings could have underestimated the relative risk of bevacizumab use.

For the same reason, other geriatric parameters such as physical performance or cognitive impairment have not been assessed. To verify if older patients are suitable for a specific chemotherapy, a comprehensive assessment with validated tools should be mandatory, in order to identify vulnerable patients with higher risk of toxicities \[[@B17]\]. Of course, clinical and laboratoristic parameters should be evaluated but, in the era of personalized cancer care, throughout the use of validated measures (Comprehensive Geriatric Assessment), the oncologist should become able to perform specific tests to determine a personalized antineoplastic treatment for elderly patients \[[@B18][@B19]\].

In conclusion, the use of bevacizumab is extremely common in OC treatment for both first- and second-line treatment and our findings suggest that its use in the elderly population should be considered as safe and manageable. Some parameters such as higher creatinine serum levels, lower eGFR according to CKD-EPI equation and number of comorbidities might be of help when establishing the risk of bevacizumab-related toxicities. We believe that these simple rules will be particularly useful in the era of combination of different target treatments, where toxicity profile can be unexpected especially in older women. Further studies including a more in-depth assessment of the geriatric population are awaited to further personalized OC treatment in the elderly.
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